Cancer Core Europe Lecture Series: "Insights into the heterogeneity of ER-positive breast Cancer – late risk of metastatic recurrence & endocrine treatment Benefit"

Breast cancer (BC) is a heterogeneous disease with the main fundamental difference being whether the tumour is hormone-sensitive or not, i.e. oestrogen receptor-positive (ER+) or negative (ER-). A unique feature of ER+ BC is the long-term risk of metastatic recurrence decades after initial diagnosis, and half or more of all BC metastases in this patient group will be diagnosed LATE i.e. beyond 5 - 10 years after diagnosis.

The factors underlying late risk of metastatic recurrence remain poorly understood. Current research is mainly focused on early risk, partly due to the lack of tumour samples from patients with complete longterm follow-up.
 
This Lecture will provide insights into Research focused on the longterm risk of metastatic disease, and how risk and endocrine treatment benefit is influenced by menopausal status and tumour biology including standard tumour markers, intra-tumour heterogeneity, and tumour microenvironment using unique clinical trials with complete longterm follow-up.

Join via Zoom
 

Meeting ID: 666 2952 4056